Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
NCT ID: NCT00812175
Last Updated: 2016-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3371 participants
OBSERVATIONAL
2009-01-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
NCT00044512
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT00105443
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT00492752
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
NCT01204177
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
NCT00703365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Sorafenib (Nexavar, BAY43-9006)
Systemic oral therapy according to product information
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib (Nexavar, BAY43-9006)
Systemic oral therapy according to product information
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have signed an informed consent form
* Patients must have a life expectancy of at least 8 weeks
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, Alabama, United States
Many Locations, Arizona, United States
Many Locations, Arkansas, United States
Many Locations, California, United States
Many Locations, Colorado, United States
Many Locations, Connecticut, United States
Many Locations, Florida, United States
Many Locations, Georgia, United States
Many Locations, Hawaii, United States
Many Locations, Illinois, United States
Many Locations, Indiana, United States
Many Locations, Iowa, United States
Many Locations, Kansas, United States
Many Locations, Kentucky, United States
Many Locations, Louisiana, United States
Many Locations, Maryland, United States
Many Locations, Massachusetts, United States
Many Locations, Michigan, United States
Many Locations, Minnesota, United States
Many Locations, Missouri, United States
Many Locations, Nebraska, United States
Many Locations, Nevada, United States
Many Locations, New Hampshire, United States
Many Locations, New Jersey, United States
Many Locations, New York, United States
Many Locations, North Carolina, United States
Many Locations, Ohio, United States
Many Locations, Oklahoma, United States
Many Locations, Oregon, United States
Many Locations, Pennsylvania, United States
Many Locations, South Carolina, United States
Many Locations, Tennessee, United States
Many Locations, Texas, United States
Many Locations, Utah, United States
Many Locations, Virginia, United States
Many Locations, Washington, United States
Many Locations, Wisconsin, United States
Many Locations, , Canada
Many Locations, , China
Many Locations, , Colombia
Many Locations, , Croatia
Many Locations, , Czechia
Many Locations, , Finland
Many Locations, , France
Many Locations, , Greece
Many Locations, , Hong Kong
Many Locations, , Hungary
Many Locations, , India
Many Locations, , Indonesia
Many Locations, , Israel
Many Locations, , Italy
Many Locations, , Japan
Many Locations, , Kazakhstan
Many Locations, , Libya
Many Locations, , Malaysia
Many Locations, , Mexico
Many Locations, , Norway
Many Locations, , Pakistan
Many Locations, , Philippines
Many Locations, , Portugal
Many Locations, , Qatar
Many Locations, , Romania
Many Locations, , Russia
Many Locations, , Singapore
Many Locations, , Slovakia
Many Locations, , South Korea
Many Locations, , Spain
Many Locations, , Sweden
Many Locations, , Syria
Many Locations, , Thailand
Many Locations, , Ukraine
Many Locations, , United Arab Emirates
Many Locations, , Uruguay
Many Locations, , Venezuela
Many Locations, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2016 Feb 9;7(6):6639-48. doi: 10.18632/oncotarget.6781.
Ye SL, Yang J, Bie P, Zhang S, Chen X, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Lv Z. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer. 2018 Mar 2;18(1):247. doi: 10.1186/s12885-018-4144-9.
Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int. 2016 Aug;36(8):1196-205. doi: 10.1111/liv.13096. Epub 2016 Apr 1.
Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010 Jul;64(8):1034-41. doi: 10.1111/j.1742-1241.2010.02414.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NX0802
Identifier Type: OTHER
Identifier Source: secondary_id
13414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.